Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine
Main Authors: | Nicholas L. Li, Karen Flores, Jason Prosek, Sergey V. Brodsky, Isabelle Ayoub |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024921015497 |
Similar Items
-
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
by: Igor Puzanov, et al.
Published: (2023-11-01) -
S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
by: C. Carlo-Stella, et al.
Published: (2022-06-01) -
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
by: Bilal H. Lashari, et al.
Published: (2018-09-01) -
Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy
by: Chiara Tarantelli, et al.
Published: (2024-05-01) -
Acute interstitial nephritis observed with three different triggering agents
by: Niloofar Nobakht, et al.
Published: (2022-03-01)